Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | MMP14 | P50281 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | RECQL | P46063 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8373371 | 1.00 | CA12 (0.54) | CA12CA1MMP2MMP9MMP8 | |
| SCHEMBL515914 | 1.00 | CA12 (0.54) | CA12CA1MMP2MMP9MMP8 | |
| Water SCHEMBL4754936 | 0.98 | CA12 (0.53) | CA12CA1MMP2MMP9MMP8 | |
| Water SCHEMBL4754935 | 0.98 | CA12 (0.53) | CA12CA1MMP2MMP9MMP8 | |
| Hydrochloric Acid SCHEMBL4754929 | 0.98 | CA12 (0.53) | CA12CA1MMP2MMP9MMP8 | |
| Glycine SCHEMBL8137571 | 0.91 | MEN1 (0.47) | CA12CA1MMP2MMP9MMP8 | |
| SCHEMBL11906704 | 0.84 | ALDH1A1 (0.44) | CA12CA1MMP2MMP9MMP8 | |
| Benzoic Acid SCHEMBL11907514 | 0.84 | KMT2A (0.49) | CA12CA1MMP2MMP9MMP8 | |
| Hydrochloric Acid SCHEMBL5967288 | 0.83 | CA12 (0.51) | CA12CA1MMP2MMP9MMP8 | |
| SCHEMBL6254462 | 0.83 | MMP9 (0.58) | CA12CA1MMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4117732-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | Ambrx, Inc. (US) | 2023-01-18 | — | — | EP | claimed |
| CN-109554437-A | A kind of dual wavelength microbial biochemical reaction dynamic interpretation detection method | 湖南长沙天地人生物科技有限公司 | 2019-04-02 | — | — | CN | claimed |
| CN-108779150-A | The Preparation Method And Their Intermediate of Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(Hor)-D-4Aph(Cbm)-Leu-Lys(iPr)-Pro-D-Ala-NH2 | 费森尤斯卡比依普莎姆责任有限公司 | 2018-11-09 | — | — | CN | claimed |
| CN-103149351-A | Synthesis and application of envelope antigen universal for pyrethriods pesticide | UNIV JIANGNAN | 2013-06-12 | — | — | CN | claimed |
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW (IL) | 2011-07-21 | — | — | US | claimed |
| EP-2262763-A2 | COMPOUNDS AND METHODS OF TREATING OBESITY | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2010-12-22 | — | — | EP | claimed |
| WO-2009109973-A2 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2009-09-11 | — | — | WO | claimed |
| US-5565328-A | COLORIMETRIC ANALYSIS WITH FLUOROMETRIC READER USING SUITABLE FLUOROPHORE | DADE INTERNATIONAL INC. (US) | 1996-10-15 | — | — | US | claimed |
| EP-4743578-A2 | THERAPY FOR ALPHA-1 ANTITRYPSIN DEFICIENCY | Precigen, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4598568-A1 | PRAME IMMUNOGENIC PEPTIDES, BINDING PROTEINS RECOGNIZING PRAME IMMUNOGENIC PEPTIDES, AND USES THEREOF | Tscan Therapeutics, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2025147774-A1 | COMPOSITIONS TARGETING BRADYKININ RECEPTOR B1 FOR MEDICAL IMAGING AND TREATMENT OF CANCER AND OTHER DISORDERS | ALPHA-9 ONCOLOGY INC. (CA) | 2025-07-17 | — | — | WO | disclosed |
| WO-2025097034-A1 | METHODS FOR MANUFACTURE OF ENGINEERED T CELLS FROM WHOLE BLOOD SAMPLES | Kyverna Therapeutics, Inc. (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-113396218-B | Engineered transaminase polypeptides | 科德克希思公司 | 2025-02-18 | — | — | CN | disclosed |
| US-12226476-B2 | Helper epitope peptide and application thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2025-02-18 | — | — | US | disclosed |
| EP-0416033-A1 | MACROCYCLIC CHELATES AND METHODS OF USE THEREOF. | US COMMERCE (US) | 1991-03-13 | — | — | EP | disclosed |
| US-4923985-A | Process for synthesizing macrocyclic chelates | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 1990-05-08 | — | — | US | disclosed |
| WO-1989011475-A1 | MACROCYCLIC CHELATES AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH (US) | 1989-11-30 | — | — | WO | disclosed |
| US-4818748-A | HYPOTENSIVE AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-04-04 | — | — | US | disclosed |
| EP-0236874-A2 | Renin inhibitors, their production and use, as well as derivatives of amino acids and amino aldehydes | BAYER AG (DE) | 1987-09-16 | — | — | EP | disclosed |
| EP-0018825-A1 | A process for the identification of bacteria and a kit of reagents for use in this process | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1980-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | GPR119, FABP4, LIPC | CA12 3310/4885CA1 1920/4885MMP2 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.